Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
AssigneeThe Regents of the University of Michigan
InventorsGeorge J. Brewer, Sofia D. Merajver, Dimitri Coucouvanis
Life of this patent
Estimating the term…
Abstract
Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.
Claims17
A composition comprising a therapeutically effective amount of tetrapropylammonium tetrathiomolybdate and a pharmaceutically acceptable excipient, said amount effective to treat an angiogenic disorder, the composition further comprising a therapeutic agent different from said tetraalkylammonium tetrathiomolybdate compound.
A kit comprising, in at least one container, a therapeutically effective amount of at least one tetraalkylammonium tetrathiomolybdate compound and:
- (a) a therapeutically effective amount of at least one therapeutic agent that is different from said tetraalkylammonium tetrathiomolybdate compound, said therapeutic agent selected from the group consisting of an anti-cancer agent and an anti-angiogenic agent;
- or (b) at least one component of an ceruloplasmin oxidase assay system for determining serum ceruloplasmin levels.
Dependencies are inferred from the claim text.